Bio-Path Holdings Presents Ongoing Phase 2 Combination Study Data at ASCO Annual Meeting

DENVER, Colo., Jun 03, 2024 (247marketnews.com)- Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, presented ongoing Phase 2 study of prexigebersen (BP1001) interim results at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2024, on behalf of Bio-Path Holdings, Inc. (NASDAQ:BPTH)

“We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients,” stated Bio-Path’s CEO, Peter Nielsen. “We continue to advance this important study confident that prexigebersen can make a difference in the lives of these patients for whom there are limited treatment options.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BPTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.